Clinical efficacy of ketotifen tablets and montelukast sodium tablets as a combination treatment for children with allergic rhinitis and their effect on serum inflammatory factors

Objective: This study was designed to evaluate the efficacy of Ketotifen Tablets and Montelukast Sodium Tablets as a combination treatment for children with allergic rhinitis and their effect on serum inflammatory factors. Methods: In total, 67 children diagnosed with allergic rhinitis in our hospital from February 2017 to November 2018 were included as study subjects, and divided into the control group (n=32) in which patients were treated with Ketotifen tablets, and the observation group (n=35) in which patients were treated with Ketotifen tablets and Montelukast Sodium tablets. Before and after treatment, patients were assessed for syndromes with TNSS and TNNSS, levels of TNF-alpha, IL-4 and IFN-gamma with ELISA, serum IgE with TINIA; and compared for clinical efficacy and effect on serum inflammatory factors (TNF-alpha, IL-4 and IFN-gamma) and serum IgE. Results: Compared with the control group, the observation group showed significant increases in clinical efficacy (P<0.05), levels of serum IL-10 and serum IFN-gamma (P<0.05), decreases in serum IgE (P<0.05), TNSS and TNNSS scores (P<0.05), levels of TNF-alpha, IL-4 and IL-10 (P<0.05), serum TNF-alpha and IL-4 (P<0.05). Conclusion: Ketotifen Tablets and Montelukast Sodium Tablets as a combination treatment can better treat allergic rhinitis by reducing TNSS and TNNSS scores, and IgE, and alleviating inflammatory reaction, over Ketotifen tablets alone.